Our Inspiration

Basic biological discoveries that truly illuminate the ontogenic paths cells take to a disease state inspire us because these insights suggest treatment strategies that are often novel and offer the prospect of superior clinical outcomes. In this era, the genomic age of medical science, the underlying genetic and gene regulatory aberrations of many conditions have been revealed but patients have not yet been the beneficiaries. Our goal is to transition those insights into medicines.

Imago’s Name

Our name, Imago, (pron. i-mắ-go), invokes the final and fully developed stage of an insect after its metamorphosis. In this process of growth and development, the imago refers to the fully formed adult, one that has completed its transformation and, for a butterfly, has taken flight. In our view, the full maturation of a scientific idea or observation in medical research is when new treatments prove their worth in clinical studies. To patients, anything less is to miss the mark.

Diseases in which cell fate and function can be influenced by epigenetic regulators

The first development program at Imago BioSciences to enter the clinic targets an enzyme essential for maintaining the disease state of a family of bone marrow disorders that includes myeloproliferative neoplasms (MPNs) as well as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These diseases are life-threatening and have proven challenging to manage and even more difficult to cure.